Opportunity
Simpler Grants.gov #FOR-FD-24-014
FDA Grant for Collaborative Regulatory Science and Drug Development Initiatives
Buyer
Food and Drug Administration
Posted
November 30, 2023
Identifier
FOR-FD-24-014
NAICS
541715, 541714
This opportunity invites organizations to collaborate with the Food and Drug Administration (FDA) to advance drug development and regulatory science through a cooperative agreement. - Government Buyer: - Food and Drug Administration (FDA) - OEMs and Vendors: - No specific OEMs or vendors are named, as this is a grant for collaborative research and development, not product procurement - Products/Services Requested: - Support, management, and facilitation of Public-Private Partnerships and collaborative activities in regulatory science - Projects in research, education, and outreach under the FDA's Critical Path Initiative - Focus on accelerating drug product development, supporting advanced manufacturing, translating basic science into therapeutics, and improving drug safety, efficacy, quality, and performance - Unique or Notable Requirements: - Open to nonprofits, educational institutions, businesses, and government entities - Emphasis on fostering public-private partnerships and innovative research - Multiple awards anticipated, each valued at $5,000,000 (subject to funding and priorities) - No specific part numbers, quantities, or OEMs due to the nature of the grant
Description
This Notice of Funding Opportunity (NOFO) invites applications for a cooperative agreement to support, manage and facilitate Public-Private Partnerships and Collaborative activities as part of the Critical Path Initiative and to support regulatory science efforts. FDA and grantees will work together to develop innovative, collaborative projects in research, education, and outreach to foster drug product innovation. The projects aim to accelerate drug product development, support advanced manufacturing, translate basic science discoveries into therapeutics, and enhance the safety, efficacy, quality, and performance of drug products. Multiple awards may be funded under this NOFO depending on drug development priorities and funding availability.